BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38698008)

  • 21. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
    Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
    World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
    Zhang X; Huang WJ; Zhang ML; Wang W; Niu Y; Wang RT; Liu ZY
    BMC Gastroenterol; 2022 Jun; 22(1):288. PubMed ID: 35668355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
    Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
    Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
    Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma.
    Yamamoto M; Ariizumi S; Otsubo T; Katsuragawa H; Katagiri S; Nakano M; Takasaki K
    J Surg Oncol; 2004 Aug; 87(2):80-3; discussion 83-4. PubMed ID: 15282700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of spectrins βI and βIII in diagnosis of hepatocellular carcinoma.
    Hu S; Jue D; Albanese J; Wang Y; Liu Q
    Ann Diagn Pathol; 2019 Apr; 39():86-91. PubMed ID: 30798076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Bösmüller H; Pfefferle V; Bittar Z; Scheble V; Horger M; Sipos B; Fend F
    Pathol Res Pract; 2018 Aug; 214(8):1136-1141. PubMed ID: 29935812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
    Wang M; Gao Y; Feng H; Warner E; An M; Jia J; Chen S; Fang M; Ji J; Gu X; Gao C
    Cancer Med; 2018 Mar; 7(3):646-654. PubMed ID: 29473340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    Julich-Haertel H; Urban SK; Krawczyk M; Willms A; Jankowski K; Patkowski W; Kruk B; Krasnodębski M; Ligocka J; Schwab R; Richardsen I; Schaaf S; Klein A; Gehlert S; Sänger H; Casper M; Banales JM; Schuppan D; Milkiewicz P; Lammert F; Krawczyk M; Lukacs-Kornek V; Kornek M
    J Hepatol; 2017 Aug; 67(2):282-292. PubMed ID: 28267620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Yang J; Zhang YH; Li JW; Shi YY; Huang JY; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Dec; 26(46):7325-7337. PubMed ID: 33362387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synchronous double cancers of primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a case report and review of the literature.
    Wu C; Bai DS; Jiang GQ; Jin SJ
    World J Surg Oncol; 2014 Nov; 12():337. PubMed ID: 25385169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.
    Rimola J; Forner A; Reig M; Vilana R; de Lope CR; Ayuso C; Bruix J
    Hepatology; 2009 Sep; 50(3):791-8. PubMed ID: 19610049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
    Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma.
    Jiang SY; Chou JM; Leu FJ; Hsu YY; Shih YL; Yu JC; Lee MS; Shyu RY
    World J Gastroenterol; 2005 Feb; 11(7):948-53. PubMed ID: 15742394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
    Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
    Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
    Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
    Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma.
    Kongtawelert P; Tangkijvanich P; Ong-Chai S; Poovorawan Y
    World J Gastroenterol; 2003 Oct; 9(10):2178-81. PubMed ID: 14562373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vivo proton magnetic resonance spectroscopy of hepatocellular carcinoma and cholangiocarcinoma].
    Dong AS; Tian JM; Lu JP; Zuo CJ; Wang L; Wang J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Apr; 31(2):151-4. PubMed ID: 19507591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.
    Lamps LW; Folpe AL
    Adv Anat Pathol; 2003 Jan; 10(1):39-43. PubMed ID: 12502967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential expression of fascin, E-cadherin and vimentin: Proteins associated with survival of cholangiocarcinoma patients.
    Mao X; Chen D; Wu J; Li J; Zhou H; Wu Y; Duan X
    Am J Med Sci; 2013 Oct; 346(4):261-8. PubMed ID: 23221510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.